11 June 2018

Designing and Monitoring Anti-NGF Imaging Endpoints

Written by Colin G. Miller



Anti-nerve growth factor (NGF) therapeutics are a new class of powerful analgesics in clinical development. But the FDA put their clinical development on hold in 2012 because joint destruction was observed in a small subset of patients. Pfizer, the leading developer of NGF compounds, needed a way to evaluate all major joints in subjects entering the new Phase III program.


Members of our group have substantial experience in imaging in osteoarthritis and NGF-targeting therapies affected joints in a similar manner, so Pfizer specifically sought us out. The solution was to:

  • Engage a team of radiologists to develop a new radiographic technique to evaluate the joints in the defined patient population.

  • Build and participate in a strong academic team that published a landmark Imaging Atlas in 2015. The book described the technique and now serves as a key clinical reference.

  • Further develop specific inter-reader training and validation techniques to reduce variability in this new arena.  The first reproducibility paper from this study has already been published.


Pfizer conducted a very successful anti-NGF program with all the radiological and MRI reads done in a reproducible and effective manner.


Providing Agile Regulatory Expertise for Teams Temporarily Under Resourced

Finding, securing, and retaining the top talent required to be an integral part of drug development..

Supporting Biotech and Pharma Companies Using Imaging Endpoints in Clinical Trials

The use of imaging endpoints in clinical trials has steadily increased over the last 30 years...